First Quarter Financial Updates
Cash and Cash Equivalents:
Based on the current operating plan and financial projections,
Conference Call and Webcast
Details for the call are as follows:
Audio-only dial-in link: click here
Webcast link: click here
Participants can use the audio-only link above to register and obtain dial-in instructions to listen to the presentation via phone and ask questions during the Q&A session, or participants can use the webcast link to register and listen and watch the slide presentation online; the replay version will be available under the same webcast link shortly after the presentation and will be archived on the Company’s website at www.nanobiotix.com. It is recommended to join 10 minutes prior to the event start. Participants are invited to email their questions in advance to investors@nanobiotix.com.
About
Incorporated in 2003,
For more information about
Disclaimer
This press release contains “forward-looking” statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the use of proceed therefrom, and the period of time through which the Company’s anticipates its financial resources will be adequate to support operations. Words such as “expects”, “intends”, “can”, “could”, “may”, “might”, “plan”, “potential”, “should” and “will” or the negative of these and similar expressions are intended to identify forward-looking statements. These forward-looking statements, which are based on our management’s current expectations and assumptions and on information currently available to management. These forward-looking statements involve known and unknown risks, uncertainties and other factors that could cause actual results to differ materially from those implied by the forward-looking statements, including risks related to Nanobiotix’s business and financial performance, which include the risk that assumptions underlying the Company’s cash runway projections are not realized. Further information on the risk factors that may affect company business and financial performance is included in Nanobiotix’s Annual Report on Form 20-F filed with the
Contacts
VP, Communications +1 (617) 852-4835 contact@nanobiotix.com | Investor Relations Department SVP, Investor Relations +1 (617) 583-0211 investors@nanobiotix.com |
Media Relations | |
FR – Ulysse Communication + 33 (0)6 13 12 04 04 lwormser@ulysse-communication.com | Global – +1 (617) 283-2856 kgardner@lifesciadvisors.com |
Attachment
- 2024-05-22 -- NBTX -- 1Q24 Financial Results -- FINAL
![](https://ml.globenewswire.com/media/ODEzNTI0MTQtNDMzNi00NGEzLWIzMGItMGE3ZGViNjI4YmM3LTEwMTExNjI=/tiny/Nanobiotix-S-A-.png)
2024 GlobeNewswire, Inc., source